Glenmark Pharma Q1 Results | Net profit plunges 86% to ₹47 crore despite stable revenue

Drug maker Glenmark Pharmaceuticals Ltd on Thursday (August 14) reported an 86.2% year-on-year (YoY) decline in net profit at ₹46.8 crore for the first quarter that ended June 30, 2025, down from ₹340.2 crore in Q1FY25.

However, revenue increased slightly, up 0.6% at ₹3,264 crore against ₹3,244 crore in the same quarter last year.

Also Read: Glenmark Pharma shares cool off after hitting 20% upper circuit post mega ISB 2001 deal

At the operating level, EBITDA dipped 1.4% to ₹580 crore in this quarter compared to ₹588.2 crore YoY. The EBITDA margin was lower at 17.7% versus 18.1% in the April-July quarter of the previous fiscal.

India sales

In India, sales from Glenmark Pharmaceuticals’ formulation business in the first quarter of FY26 stood at ₹1,239.9 crore, compared with ₹1,196.2 crore a year ago, reflecting a 3.7% YoY growth.

North America business 

In North America, the business registered revenue of ₹778 crore for this quarter, compared with ₹714.6 crore in the fourth quarter of FY25, marking an 8.9% quarter-on-quarter (QoQ) increase. The growth was driven by share gains in injectable product launches and partnered products.

Also Read: Glenmark Pithampur warning letter accessed by CNBC-TV18: Details here

Revenue from emerging markets, including RCIS, LATAM, MEA, and APAC, was ₹572.1 crore in the first quarter of FY26, compared with ₹570.8 crore in the year-ago period, registering a 0.2% YoY rise. The company continues to anticipate double-digit growth on a constant currency basis.

In Europe, revenue fell 4% in this quarter at ₹6,678 million, compared with ₹6,957 million a year ago.

Product launches

As of June 2025, marketing applications for Ryaltris (nasal spray) have been submitted to more than 90 countries, with the product commercialised in over 45 markets. It is expected to be launched in an additional 10-12 markets over the next few quarters. Glenmark has filed applications for oncology drug QiNHAYO (envafolimab) in approximately 15 markets in FY25, with the first market launch anticipated in FY26.

The company, in partnership with Cosmo, received approval from the Medicines and Healthcare Products Regulatory Agency (MHRA) to market Winlevi (acne treatment) in the United Kingdom. Winlevi has been launched in the UK, and approval in other European markets is expected by the end of FY26.

Also Read: Glenmark Pharmaceuticals' USA arm reaches $37.75 million settlement in US antitrust lawsuit

The results came after the close of the market hours. Shares of Glenmark Pharmaceuticals Ltd ended at ₹2,038.95, up by ₹7.15 or 0.35%, on the BSE today (August 14).